Fig. 5.

CDK9 inhibition by siRNA decreased osteosarcoma cell proliferation by suppression of the RNAPII phosphorylation pathway. Cell viability of (A) U2OS and (B) KHOS, determined by MTT assays measured at 490 nm after CDK9 siRNA negative control (NC) siRNA transfection. The data is mean ± SE of the 2 experiments carried out in triplicate. The expression of respective proteins in CDK9-associated signaling pathway was measured by Western blotting in the osteosarcoma cell lines (C) U2OS, and (D) KHOS after 72 h of siRNA transfection. (** indicates P < .01).